Dr Reddy's stock drops in trading today
The open price of Dr Reddy's stock was 4915.05 in the current session. The highest price reached during the session was 4967.7, while the lowest price was 4887.05.08-05-2023
08-05-2023
Dr Reddy's Laboratories launches Regadenoson injection in US market
Dr Reddy's Laboratories Ltd on Friday announced the launch of Regadenoson injection, used as an agent in the imaging of heart muscle to check blood flow, in the US market. Regadenoson injection is supplied as single-dose pre-filled syringes, 0.4mg/5ml (0.08 mg/ml). It is a generic therapeutic equivalent of Lexiscan injection, approved by US Food and Drug Administration (USFDA), Dr Reddy's said in a regulatory filing. The injection is a pharmacologic stress agent for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress. In a separate filing, Dr Reddy's said it has issued a Form 483 with one observation by the USFDA after a routine GMP inspection at its API manufacturing facility (CTO 1) in Bollaram, Hyderabad. "The inspection was conducted from May 1, 2023 to May 5, 2023. We have been issued a Form 483 with one observation, which we will address within the stipulated timeline," the company said. As per USFDA, Form 483 is issued to a05-05-2023
DR.REDDY'S LABORATORIES LTD. - 500124 - Intimation
Intimation about USFDA audit at our CTO 1 unit at Bollaram05-05-2023
DR.REDDY'S LABORATORIES LTD. - 500124 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press release on Dr. Reddy''s Laboratories announces the launch of Regadenoson Injection 0.4 mg/5 mL in the U.S.05-05-2023
DR.REDDY'S LABORATORIES LTD. - 500124 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press release on Dr. Reddy''s Laboratories announces the launch of Regadenoson Injection 0.4 mg/5 mL in the U.S.05-05-2023
DR.REDDY'S LABORATORIES LTD. - 500124 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Loss of Share Certificates28-04-2023
DR.REDDY'S LABORATORIES LTD. - 500124 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyDR.REDDY''S LABORATORIES LTD. 2CIN NO.L85195TG1984PLC004507 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: K Randhir Singh Designation: Company Secretary and Compliance Officer EmailId: [email protected] Name of the Chief Financial Officer: Parag Agarwal Designation: Chief Financial Officer EmailId: [email protected] Date: 28/04/2023 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.28-04-2023
DR.REDDY'S LABORATORIES LTD. - 500124 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Earnings call intimation Q4 FY2322-04-2023
Dr Reddy's launches generic Treprostinil injection
The launched product is a therapeutic equivalent genericversion of Remodulin (treprostinil) Injection, approved by the USFDA21-04-2023
DR.REDDY'S LABORATORIES LTD. - 500124 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Dr. Reddy''s Laboratories announces the launch of Treprostinil Injection in the U.S.21-04-2023